Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases
Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases
复制标题
DOI：
10.7717/peerj.8298
复制
发表时间：
2019-12-17
期刊：
影响因子：
2.7
通讯作者：
Lyu, Jun
中科院分区：
文献类型：
--
作者：
Chen, Siying;Yang, Jin;Lyu, Jun
背景：关于不同亚型乳腺癌患者诊断时肺转移的发生率和预后的报道有限。我们的研究探讨了分子亚型分层对肺转移性乳腺癌患者预后的影响。方法：从2010年至2015年的监测、流行病学和最终结果人群数据中确定乳腺癌和肺转移患者。单变量和多变量考克斯回归分析，以确定危险因素和疾病，总生存期（OS）和乳腺癌特异性生存的乳腺癌肺转移patients with breast cancer lung metastases.Results：我们确定了6,516例肺转移性乳腺癌患者，占整个队列的1.7%和30.4%的转移性疾病的子集。其中包括2，940例激素受体（HR）+/HER 2-患者、852例HR+/HER 2+患者、547例HR-/HER 2+患者和983例三阴性患者。所有肺转移患者的中位OS为13个月。多变量分析显示，年龄较大（>80岁）、黑人、肿瘤分化差、癌组织学类型、三阴性亚型、转移部位较多且未手术、未化疗的肺转移性乳腺癌患者总体生存率和乳腺癌特异性生存率均显著较差。我们的研究结果表明，分子亚型和更多的转移部位可能对乳腺癌肺转移的发生率和预后有显着影响。我们还确定了几个预后因素，可以指导治疗肺转移患者的治疗选择。
Background: Reports on the incidence and prognoses of lung metastases when diagnosing breast cancer patients with different subtypes are limited. Our study investigated the effect of molecular sub-typing stratification on the prognoses of lung metastatic breast caner patients.Methods: Patients with breast cancer and lung metastases were identified from Surveillance, Epidemiology and End Results population-based data between 2010 and 2015. Univariate and multivariate Cox regression analyses were performed to identify risk factors and prognoses, overall survival (OS) and breast cancer-specific survival for patients with breast cancer lung metastases.Results: We identified 6,516 patients with lung metastatic breast cancer, representing 1.7% of the entire cohort and 30.4% of the subset with metastatic disease. This included 2,940 hormone receptor (HR)+/HER2- patients, 852 HR+/HER2+ patients, 547 HR-/HER2+ patients and 983 triple-negative patients. The median OS for all lung metastatic patients was 13 months. Multivariate analysis revealed that those lung metastatic breast cancer patients of older age (>80), black race, with poorly differentiated tumors, carcinoma histology, triple-negative subtype, more metastatic sites and no surgery, and no chemotherapy showed significantly poor survival, both overall and breast cancer-specific.Conclusions: Our findings show that molecular sub-type and more metastatic sites might have significant influence on the incidence and prognosis of breast cancer lung metastases. We also identified several prognostic factors that could guide therapy selection in the treatment of lung metastatic patients.